- Home
- IKT vs RCEL Comparison
IKT vs RCEL Comparison
Compare IKT & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IKT
- RCEL
- Stock Information
- Founded
- IKT 2008
- RCEL N/A
- Country
- IKT United States
- RCEL United States
- Employees
- IKT N/A
- RCEL N/A
- Industry
- IKT Biotechnology: Pharmaceutical Preparations
- RCEL Medical/Dental Instruments
- Sector
- IKT Health Care
- RCEL Health Care
- Exchange
- IKT Nasdaq
- RCEL Nasdaq
- Market Cap
- IKT 123.7M
- RCEL 107.8M
- IPO Year
- IKT 2020
- RCEL N/A
- Fundamental
- Price
- IKT $1.53
- RCEL $3.97
- Analyst Decision
- IKT Buy
- RCEL Buy
- Analyst Count
- IKT 2
- RCEL 5
- Target Price
- IKT $8.00
- RCEL $11.80
- AVG Volume (30 Days)
- IKT 96.5K
- RCEL 242.3K
- Earning Date
- IKT 11-13-2025
- RCEL 11-06-2025
- Dividend Yield
- IKT N/A
- RCEL N/A
- EPS Growth
- IKT N/A
- RCEL N/A
- EPS
- IKT N/A
- RCEL N/A
- Revenue
- IKT N/A
- RCEL $74,884,000.00
- Revenue This Year
- IKT N/A
- RCEL $22.92
- Revenue Next Year
- IKT N/A
- RCEL $37.07
- P/E Ratio
- IKT N/A
- RCEL N/A
- Revenue Growth
- IKT N/A
- RCEL 38.32
- 52 Week Low
- IKT $1.42
- RCEL $3.60
- 52 Week High
- IKT $4.20
- RCEL $14.16
- Technical
- Relative Strength Index (RSI)
- IKT 41.85
- RCEL 31.75
- Support Level
- IKT $1.53
- RCEL $3.84
- Resistance Level
- IKT $1.67
- RCEL $4.25
- Average True Range (ATR)
- IKT 0.11
- RCEL 0.26
- MACD
- IKT -0.00
- RCEL -0.18
- Stochastic Oscillator
- IKT 19.64
- RCEL 6.94
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
About RCEL Avita Medical Inc.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in rollout across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.